AnaptysBio Inc (ANAB)
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing immunology therapies for autoimmune and inflammatory diseases. The company is advancing a pipeline that includes Rosnilimab, a selective pathogenic T-cell depleter that has completed a Phase 2b study in moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist in Phase 1b development for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody in Phase 1a testing; and Imsidolimab, an interleukin-36 receptor inhibitor in Phase 3 development for generalized pustular psoriasis. Its portfolio also includes dostarlimab for multiple solid tumor indications. AnaptysBio develops these programs partly through collaborations, including agreements with GSK and Vanda. The company was incorporated in 2005, formerly operated under the name Anaptys Biosciences, Inc., and is based in San Diego, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ANAB
|
$58.62
|
28.6% Upside
|
Undervalued
|
$87.25
|
91.4% Upside
|
Bargain
|
Good
|
47.4%
|
November 11, 2026
|
3.9x
|
128.7x
|
12.8x
|
1.363 B
|
1.468 B
|
16.0%
|
68.6%
|
1.6
|
-29.8%
|
